Stockman Wealth Management Inc. cut its holdings in Johnson & Johnson (NYSE:JNJ) by 6.7% in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 11,550 shares of the company’s stock after selling 829 shares during the quarter. Stockman Wealth Management Inc.’s holdings in Johnson & Johnson were worth $1,515,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in the company. Tamarack Advisers LP bought a new position in Johnson & Johnson in the fourth quarter valued at about $18,035,000. Orser Capital Management LLC boosted its holdings in Johnson & Johnson by 44.2% in the fourth quarter. Orser Capital Management LLC now owns 1,875 shares of the company’s stock valued at $272,000 after acquiring an additional 575 shares during the last quarter. Exchange Traded Concepts LLC bought a new position in Johnson & Johnson in the fourth quarter valued at about $31,000. Arkfeld Wealth Strategies L.L.C. bought a new position in Johnson & Johnson in the fourth quarter valued at about $536,000. Finally, SeaCrest Wealth Management LLC boosted its holdings in Johnson & Johnson by 5.8% in the fourth quarter. SeaCrest Wealth Management LLC now owns 49,644 shares of the company’s stock valued at $7,241,000 after acquiring an additional 2,718 shares during the last quarter. Institutional investors own 67.66% of the company’s stock.

In other Johnson & Johnson news, Director William D. Perez acquired 500 shares of the business’s stock in a transaction dated Friday, March 13th. The shares were acquired at an average price of $127.69 per share, for a total transaction of $63,845.00. Following the acquisition, the director now directly owns 16,030 shares of the company’s stock, valued at approximately $2,046,870.70. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 0.27% of the company’s stock.

Several equities analysts recently issued reports on JNJ shares. Citigroup raised their price target on Johnson & Johnson from $150.00 to $165.00 and gave the company a “buy” rating in a report on Wednesday, April 15th. UBS Group cut Johnson & Johnson from a “buy” rating to a “neutral” rating and reduced their target price for the stock from $163.00 to $160.00 in a report on Tuesday, April 28th. Stifel Nicolaus raised their target price on Johnson & Johnson from $140.00 to $155.00 and gave the stock a “hold” rating in a report on Wednesday, April 15th. SVB Leerink reduced their target price on Johnson & Johnson from $172.00 to $160.00 and set an “outperform” rating on the stock in a report on Wednesday, April 8th. Finally, Cantor Fitzgerald restated a “buy” rating and set a $168.00 target price on shares of Johnson & Johnson in a report on Tuesday, April 28th. Four research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $163.47.

NYSE:JNJ opened at $144.37 on Friday. Johnson & Johnson has a fifty-two week low of $109.16 and a fifty-two week high of $157.00. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.31 and a quick ratio of 1.05. The stock has a market capitalization of $386.52 billion, a PE ratio of 16.52, a price-to-earnings-growth ratio of 3.19 and a beta of 0.71. The business’s 50-day simple moving average is $146.81 and its 200-day simple moving average is $142.30.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Tuesday, April 14th. The company reported $2.30 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.03 by $0.27. Johnson & Johnson had a return on equity of 39.71% and a net margin of 24.47%. The business had revenue of $20.69 billion for the quarter, compared to analysts’ expectations of $19.48 billion. During the same quarter in the previous year, the business posted $2.10 EPS. Johnson & Johnson’s revenue for the quarter was up 3.3% on a year-over-year basis. On average, research analysts expect that Johnson & Johnson will post 7.68 earnings per share for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 9th. Stockholders of record on Tuesday, May 26th will be issued a dividend of $1.01 per share. This represents a $4.04 annualized dividend and a dividend yield of 2.80%. The ex-dividend date of this dividend is Friday, May 22nd. This is a boost from Johnson & Johnson’s previous quarterly dividend of $0.95. Johnson & Johnson’s payout ratio is 43.78%.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Read More: Portfolio Manager

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.